Trial Profile
A Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) in Combination With Everolimus in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in NSCLC Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Ceritinib (Primary) ; Everolimus
- Indications Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- 20 Jun 2023 Planned End Date changed from 30 Jun 2023 to 31 Dec 2024.
- 20 Jun 2023 Planned primary completion date changed from 30 Jun 2023 to 31 Dec 2024.
- 27 Jun 2022 Status changed from recruiting to active, no longer recruiting.